While both CTLA-4 and PD-1 blockade were first shown to be effective in advanced melanoma, subsequent clinical experience has demonstrated that PD-1/PD-L1 inhibition is generally safer and more effective than CTLA-4 blockade when used as monotherapy [7]. This evidence concerns the gene CTLA4 and melanoma.